Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Research & Development (2017 - 2025)

Aclaris Therapeutics has reported Research & Development over the past 9 years, most recently at $16.6 million for Q4 2025.

  • Quarterly results put Research & Development at $16.6 million for Q4 2025, up 83.74% from a year ago — trailing twelve months through Dec 2025 was $52.6 million (up 56.75% YoY), and the annual figure for FY2025 was $52.6 million, up 56.75%.
  • Research & Development for Q4 2025 was $16.6 million at Aclaris Therapeutics, up from $13.0 million in the prior quarter.
  • Over the last five years, Research & Development for ACRS hit a ceiling of $26.6 million in Q4 2023 and a floor of $6.0 million in Q3 2024.
  • Median Research & Development over the past 5 years was $14.0 million (2021), compared with a mean of $15.3 million.
  • Biggest five-year swings in Research & Development: surged 137.8% in 2022 and later tumbled 75.05% in 2024.
  • Aclaris Therapeutics' Research & Development stood at $14.1 million in 2021, then skyrocketed by 49.43% to $21.1 million in 2022, then increased by 26.45% to $26.6 million in 2023, then crashed by 66.13% to $9.0 million in 2024, then skyrocketed by 83.74% to $16.6 million in 2025.
  • The last three reported values for Research & Development were $16.6 million (Q4 2025), $13.0 million (Q3 2025), and $11.4 million (Q2 2025) per Business Quant data.